Literature DB >> 15739656

Preventing the occurrence of pressure ulceration in hospitalised elderly patients.

S Meaume1, D Colin, B Barrois, S Bohbot, F A Allaert.   

Abstract

OBJECTIVE: To determine which factors contribute to the development of pressure ulcers and to evaluate the role of topical agents in preventing their occurrence.
METHOD: An observational, prospective survey covered 36 care of the elderly wards and involved 1121 patients at high or very high risk of pressure ulceration. The patients, of whom 667 (59.6%) received a gentle application of a topical agent to at-risk areas, were followed up for eight weeks.
RESULTS: Of the patients, 15.7% developed a pressure ulcer. The use of a corpitolinol 60-based topical agent (Sanyrène/Corpitol) significantly reduced the incidence of pelvic pressure ulcers (p=0.04) when used with recognised prevention strategies. This was identified by undertaking a logistic regression analysis. The resulting odds ratio of 0.61 indicates that the intervention helped to reduce the number of pressure ulcers by 40%.
CONCLUSION: The results of this observational study can provide a useful guide to the design of further randomised controlled trials.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15739656     DOI: 10.12968/jowc.2005.14.2.26741

Source DB:  PubMed          Journal:  J Wound Care        ISSN: 0969-0700            Impact factor:   2.072


  3 in total

1.  IPARZINE-SKR study: randomized, double-blind clinical trial of a new topical product versus placebo to prevent pressure ulcers.

Authors:  José Verdú; Javier Soldevilla
Journal:  Int Wound J       Date:  2012-10       Impact factor: 3.315

2.  Methodological issues in studies of the effectiveness of pressure ulcer prevention interventions.

Authors:  Mona Baumgarten; Michelle Shardell; Shayna Rich
Journal:  Adv Skin Wound Care       Date:  2009-04       Impact factor: 2.347

3.  Comparison of polyurethane foam dressing and hydrocolloid dressing in patients with pressure ulcers: A randomized controlled trial protocol.

Authors:  Yan Jin; Jun Li; Shuai Wu; Fei Zhou
Journal:  Medicine (Baltimore)       Date:  2021-01-15       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.